Quince Therapeutics Inc (QNCX)

Dec 21, 2024

Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World

Dec 21, 2024

Dec 20, 2024

Brookline Capital Management Predicts QNCX FY2024 Earnings - MarketBeat

Dec 20, 2024

Dec 19, 2024

Quince Therapeutics initiated with a Buy at Brookline - MSN

Dec 19, 2024

Dec 18, 2024

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Dec 18, 2024

Dec 18, 2024

Brookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat

Dec 18, 2024

Dec 18, 2024

Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com

Dec 18, 2024

Dec 18, 2024

Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Dec 18, 2024

Dec 16, 2024

Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat

Dec 16, 2024

Dec 10, 2024

Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World

Dec 10, 2024

Nov 30, 2024

Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat

Nov 30, 2024

Nov 30, 2024

QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 22, 2024

Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World

Nov 22, 2024

Nov 22, 2024

QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Nov 21, 2024

Nov 21, 2024

QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com

Nov 21, 2024

Nov 16, 2024

Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat

Nov 16, 2024

Nov 15, 2024

QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia

Nov 15, 2024

Nov 14, 2024

Quince Therapeutics regains Nasdaq compliance - Investing.com

Nov 14, 2024

Nov 13, 2024

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire

Nov 13, 2024

Nov 12, 2024

Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire

Nov 12, 2024

Nov 11, 2024

Quince Therapeutics reports positive safety data for EryDex - Investing.com India

Nov 11, 2024

Nov 11, 2024

Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK

Nov 11, 2024

Nov 11, 2024

Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan

Nov 11, 2024

Nov 08, 2024

Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM

Nov 08, 2024

Nov 07, 2024

Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat

Nov 07, 2024

Nov 07, 2024

This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Nov 07, 2024

Oct 31, 2024

Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World

Oct 31, 2024

Oct 30, 2024

QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK

Oct 30, 2024

Oct 30, 2024

Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Oct 30, 2024

Oct 29, 2024

Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com

Oct 29, 2024

Oct 24, 2024

US Penny Stocks To Watch In October 2024 - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada

Oct 23, 2024

Oct 14, 2024

Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire

Oct 14, 2024

Sep 25, 2024

Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World

Sep 25, 2024

Sep 20, 2024

Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals

Sep 20, 2024

Sep 12, 2024

Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR

Sep 12, 2024

Sep 04, 2024

Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World

Sep 04, 2024

Sep 03, 2024

Quince Therapeutics CEO acquires $107k in company stock - Investing.com

Sep 03, 2024

Sep 03, 2024

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 03, 2024

Sep 02, 2024

The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily

Sep 02, 2024

Sep 02, 2024

Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News

Sep 02, 2024

Sep 02, 2024

Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News

Sep 02, 2024

Aug 24, 2024

Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 24, 2024

Aug 23, 2024

Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 23, 2024

Aug 22, 2024

Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com India

Aug 22, 2024

Aug 21, 2024

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN

Aug 21, 2024

Aug 19, 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha

Aug 19, 2024

Aug 17, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World

Aug 17, 2024

Aug 16, 2024

Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena

Aug 16, 2024